Results 41 to 50 of about 10,218 (198)

EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER)

open access: yesРациональная фармакотерапия в кардиологии, 2016
Aim. To study efficacy and safey of sinus rhythm restoration with amiodarone and propafenone in outpatients with recurrent atrial fibrillation (AF), and to estimate pharmacoeconomic efficiency of such cardioversion in comparison with hospital treatment ...
T. A. Istomina   +6 more
doaj   +1 more source

Advances in cardiac devices and bioelectronics augmented with artificial intelligence

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Interfaces between the human heart, diagnostic bioelectronics, artificial intelligence, and clinical care. From left to right: Human heart and biosensor interface; representative waveforms of common diagnostic bioelectronic sensing modalities.
Charles Stark   +3 more
wiley   +1 more source

Rate-Control or Rhythm-Contol: Where do we stand? [PDF]

open access: yes, 2005
Atrial fibrillation is the most common sustained rhythm disturbance and its prevalence is increasing worldwide due to the progressive aging of the population.
A, Dello Russo   +6 more
core   +1 more source

Flecainide reduces Ca2+ spark and wave frequency via inhibition of the sarcolemmal sodium current [PDF]

open access: yes, 2013
AIMS: Ca(2+) waves are thought to be important in the aetiology of ventricular tachyarrhythmias. There have been conflicting results regarding whether flecainide reduces Ca(2+) waves in isolated cardiomyocytes.
Collins, TP   +8 more
core   +1 more source

PROPAFENONE FOR SINUS RHYTHM RECOVERY AND SUPPORT IN PATIENTS WITH PERSISTENT FORM OF AURICULAR FIBLILLATION. “PROMETHEUS” – OPENED MULTICENTER STUDY IN RUSSIAN FEDERATION

open access: yesРациональная фармакотерапия в кардиологии, 2016
Aim. To study efficiency and safety of propafenone internally used for recovery and support of sinus rhythm in patients with the persistent form of auricular fibrillation (AF). Material and methods. 503 patients with the persistent form of AF, aged 31-68
I. G. Fomina   +2 more
doaj   +2 more sources

Propafenone and propranolol dual toxicity

open access: yesJournal of the American College of Emergency Physicians Open, 2020
Propranolol is a highly lipid‐soluble beta‐receptor antagonist and propafenone is a potent class 1c anti‐arrhythmic agent with strong Na‐channel blockade effect.
Moonis Farooq   +3 more
doaj   +1 more source

Characterisation of the Na, K pump current in atrial cells from patients with and without chronic atrial fibrillation [PDF]

open access: yes, 2003
<b>Objective:</b> To assess the contribution of the Na, K pump current (<i>I</i><sub>p</sub>) to the action potential duration (APD) and effective refractory period (ERP) in human atrial cells, and to investigate ...
Kane, K.A., Rankin, A.C., Workman, A.J.
core   +1 more source

Chronic Propafenone Application Increases Functional KIR2.1 Expression In Vitro

open access: yesPharmaceuticals, 2023
Expression and activity of inwardly rectifying potassium (KIR) channels within the heart are strictly regulated. KIR channels have an important role in shaping cardiac action potentials, having a limited conductance at depolarized potentials but ...
Encan Li   +3 more
doaj   +1 more source

Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 935-945, February 2026.
Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang   +5 more
wiley   +1 more source

Pharmacotherapy Risks in Rare Genetic Diseases: Cross‐Referencing ACMG Secondary Findings v3.2 List With Clinical Databases

open access: yesClinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT Clinical genomics and pharmacogenomics have largely remained separate fields, though some genetic variants have overlapping disease risk and drug implications. However, the extent of this overlap is not well studied. To explore this gap, we cross‐referenced genes from the American College of Medical Genetics Secondary Findings v3.2 list with ...
Josiah D. Allen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy